Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020538 (hypertension)
 170,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

It is estimated that 60%-7% of women of reproductive age have polycystic ovarian syndrome (PCOS). Women with this condition exhibit an adverse cardiovascular risk profile, characteristic of the cardiometabolic syndrome and given the high prevalence of PCOS in the female population, this condition may contribute towards the acceleration of cardiovascular disease among young women. This article summarizes the recent development and findings in the cardiometabolic abnormalities in patients with PCOS. Patients with PCOS have the clinical features of oligomenorrhoea, hirsutism and infertility; however, they also exhibit hyperinsulinemia, obesity, hypertension, dyslipidemia, and an increased pro-thrombotic state. They have an increased risk of type 2 diabetes and impaired glucose tolerance, and sleep apnea is also found more commonly in this population. However, despite the presence of cardiovascular risk factors and increased surrogate markers of cardiovascular disease it is unclear if they have accelerated atherosclerosis. End point studies are currently lacking and the available evidence are conflicting. Adipose tissue has emerged as an important endocrine organ over the last decade and gained recognition in having an important role in the cardiometabolic syndrome. Adiponectin that is secreted exclusively by adipocytes has recently been recognized as an important marker of cardiometabolic syndrome, obesity, type 2 diabetes, and coronary artery disease. Other adipocytokines like leptin and resistin have also recently been recognized. This article will address the current evidence for the adverse cardiovascular risk in PCOS and the other factors that may be implicated. Finally the therapeutic options for treatment will be discussed.
 ...
PMID:Cardiometabolic aspects of polycystic ovarian syndrome. 1758 75

Polycystic ovary syndrome (PCOS) is commonly associated with insulin resistance, obesity, dyslipidemia and hypertension. Adiponectin, an adipocyte-specific protein with important roles in glucose and lipid homeostasis, possesses antidiabetic and insulin-sensitizing properties. Ghrelin, a protein ligand for the growth hormone secretagog receptor, has been shown to stimulate food intake and to influence energy balance, insulin signaling and glucose metabolism. We aimed to evaluate the relationships between metabolic alterations and adiponectin and ghrelin levels in lean PCOS women, compared with lean and obese women. The study was carried out on 20 non-obese PCOS women aged 20 - 48 years and age-matched groups of 45 healthy lean and 37 obese women. Hormonal and biochemical parameters, adiponectin and ghrelin concentrations and anthropometric data were determined. In PCOS subjects, we found increased homeostasis model assessment - insulin resistance index (HOMA-IR) with non-significant differences in adiponectin and ghrelin concentrations compared with healthy women, although the PCOS group showed a tendency to lower adiponectin levels. However, ghrelin levels in PCOS women were significantly higher than in obese women. Moreover, we observed a negative correlation between adiponectin and testosterone, cholesterol, triglycerides, glucose and diastolic blood pressure in PCOS. In conclusion, it can be suggested that higher values of HOMA-IR with lower adiponectin levels may indicate future development of metabolic syndrome or other metabolic disturbances in lean PCOS women.
 ...
PMID:The relationship between metabolic status and levels of adiponectin and ghrelin in lean women with polycystic ovary syndrome. 1761 56

Adiponectin has demonstrated insulin-sensitizing, antiatherogenic, and anti-inflammatory properties, and may be an important risk factor for coronary heart disease and diabetes. Relatively few previous studies of plasma adiponectin have included sizable numbers of African Americans. The objective of the study was to investigate plasma concentrations of adiponectin and correlates of these concentrations in African Americans. This was a cross-sectional analysis that took place within the Hypertension Genetic Epidemiology Network. This study included 211 normotensive offspring (aged 22-37 years) of hypertensive siblings recruited by the Hypertension Genetic Epidemiology Network Birmingham, AL, field center. In addition to measuring plasma adiponectin, demographic and lifestyle data were collected, and anthropometric, clinical, and laboratory measurements were obtained. Mean plasma adiponectin concentration was 5.5+/-3.8 microg/mL. Adiponectin was 55% higher in women than in men: 6.5+/-4.4 vs 4.2+/-2.5 microg/mL, respectively (P<.0001). In a multivariable analysis, high-density lipoprotein cholesterol concentration was positively associated and male sex and insulin concentration were negatively associated with plasma adiponectin concentration. Plasma adiponectin concentrations in these African Americans were lower than those reported in other racial/ethnic groups, including Japanese, whites, and Pima Indians. The directions of the associations of plasma adiponectin with other factors were in agreement with results in other racial/ethnic groups.
 ...
PMID:Plasma adiponectin concentrations and correlates in African Americans in the Hypertension Genetic Epidemiology Network (HyperGEN) study. 1761 43

Adiponectin plays an important role in the development of various lifestyle-related diseases such as obesity, hypertension, type II diabetes mellitus, hyperlipidemia, and metabolic syndrome, leading to the development of heart and vascular diseases. However, the determinants that affect circulating adiponectin levels, including lifestyle factors, have still not been thoroughly investigated, in a general male population in particular. A total of 109 healthy Japanese male subjects (mean age, 55 +/- 14 years) with constant lifestyles were enrolled. All were on no medication. Fasting serum adiponectin levels were measured with an enzyme-linked immunosorbent assay. Each subject's lifestyle was assessed by the self-administered Breslow Questionnaire (a well-established method to estimate various lifestyles) with minor modifications. Partial correlation analysis for serum adiponectin levels, after controlling age and all lifestyle factors, revealed a significant and independent negative correlation between serum adiponectin levels and body mass index (BMI) (r = -0.222, P = 0.025), and a significant and independent positive correlation between serum adiponectin levels and sleep duration (r = 0.252, P = 0.011). No significant correlations were observed between adiponectin and other lifestyle factors. These data suggest that increased BMI and shorter sleep duration may be significant independent risks for low serum adiponectin levels in healthy males. Therefore, these factors may be intervention targets to modulate adiponectin to its proper levels for the prevention of cardiovascular disorders.
 ...
PMID:Serum adiponectin levels and lifestyle factors in Japanese men. 1787 19

About 20 years ago, Reaven presented the concept that a series of related factors such as hyperinsulinemia, hypertension, low high-density lipoprotein (HDL)-cholesterol levels, and hypertriglyceridemia tended to co-occur in the same individual and that this risk-factor clustering and its association with insulin resistance might be of critical importance in the underlying cause of cardiovascular disease. This risk-factor clustering called as "syndrome X" has now become "metabolic syndrome" (METS). Nowadays, METS is becoming well known as a condition of high-risk for the subsequent development of ischemic cardiovascular disease in Western population as well as Japanese population and it is proved that the prevalence of METS is very common. There are several different diagnostic definitions for METS. In Japanese definition, waist circumference is essential for criterion of METS because visceral fat accumulation is believed to be associated with METS more closely than the body mass index (BMI) itself or the amount of subcutaneous fat. Therefore treatment strategy to reduce visceral fat seems to be crucial for management of patients with METS. Adipose tissue is not simply an energy storage organ, but also a secretary organ, producing a variety of bioactive substances, including adiponectin. Adiponectin is paradoxically reduced in obesity and elevated adiponectin concentration is associated with greater insulin sensitivity. Therefore hypoadiponectinemia can be considered a key factor of the development of METS. We believe that detection, prevention and treatment of METS are important clinical and public health challenges.
 ...
PMID:[Metabolic syndrome]. 1792 6

Adiponectin is a major adipocytokine and has been considered as an independent risk factor for arterial hypertension. Most studies on the subject have been restricted to biracial (white-black) and Asian groups. The present report examined whether adiponectin affects blood pressure in a sample of untreated obese Brazilians of multiethnic origin. Fasting plasma adiponectin and serum insulin were determined by radioimmunoassay. Insulin resistance was estimated by homeostatic model assessment of insulin resistance (HOMA-IR). Blood pressure was recorded using Dinamap 1846 (Critikon, Tampa, FL). Adiponectin was significantly lower in obese hypertensive individuals than in obese normotensive ones. Blood pressure, insulin, and HOMA-IR were significantly higher in obese hypertensive than in obese normotensive individuals. Plasma adiponectin was negatively associated with waist-to-hip ratio, blood pressure, insulin, and HOMA-IR. The comparison of obese individuals who markedly differed in their HOMA-IR (> vs <or=2.71) showed that the association of adiponectin and blood pressure remained significant only in obese insulin-resistant individuals, whose adiponectin showed a positive association with high-density lipoprotein cholesterol. Stepwise regression analysis revealed that HOMA-IR, adiponectin, body mass index, and age independently affected the risk for increased systolic blood pressure, with HOMA-IR the strongest of them all. Finally, when patients were stratified into tertiles of HOMA-IR and further classified according to the 50th percentile of adiponectin (<or= vs >6. 5 microg/mL), a 3 x 2 analysis of variance showed an independent contribution of adiponectin in the variation of mean arterial pressure. These results support the notion that HOMA-IR and adiponectin independently predict blood pressure variation in obese insulin-resistant Brazilians.
 ...
PMID:Hypoadiponectinemia is associated with blood pressure increase in obese insulin-resistant individuals. 1795 95

Adiponectin is a major adipocyte-secreted adipokine abundantly present in the circulation as three distinct oligomeric complexes. In addition to its role as an insulin sensitizer, mounting evidence suggests that adiponectin is an important player in maintaining vascular homoeostasis. Numerous epidemiological studies based on different ethnic groups have identified adiponectin deficiency (hypoadiponectinaemia) as an independent risk factor for endothelial dysfunction, hypertension, coronary heart disease, myocardial infarction and other cardiovascular complications. Conversely, elevation of circulating adiponectin concentrations by either genetic or pharmacological approaches can alleviate various vascular dysfunctions in animal models. Adiponectin exerts its vasculoprotective effects through its direct actions in the vascular system, such as increasing endothelial NO production, inhibiting endothelial cell activation and endothelium-leucocyte interaction, enhancing phagocytosis, and suppressing macrophage activation, macrophage-to-foam cell transformation and platelet aggregation. In addition, adiponectin reduces neointima formation through an oligomerization-dependent inhibition of smooth muscle proliferation. The present review highlights recent research advances in unveiling the molecular mechanisms that underpin the vascular actions of adiponectin and discusses the potential strategies of using adiponectin or its signalling pathways as therapeutic targets to combat obesity-related metabolic and vascular diseases.
 ...
PMID:Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. 1823 60

Studies performed during the last decade indicate that adipose tissue is not only a site of triglyceride storage but also an active endocrine organ which secretes many biologically active mediators referred to as "adipokines". In contrast to many adipokines which are overproduced in obese individuals and exert deleterious effects on insulin sensitivity, lipoprotein metabolism and cardiovascular system, such as leptin, tumor necrosis factor-alpha, plasminogen activator inhibitor-1, resistin, etc., adiponectin seems to be a unique adipokine which is produced in lower amounts in obese than in lean subjects and possesses predominantly beneficial activities, i.e. increases insulin sensitivity, stimulates fatty acid oxidation, inhibits inflammatory reaction and induces endothelium-dependent nitric oxide-mediated vasorelaxation. Adiponectin binds two receptors, AdipoR1 and AdipoR2. Adiponectin knockout mice exhibit various manifestations of the metabolic syndrome such as insulin resistance, glucose intolerance, hyperlipidemia, impaired endothelium-dependent vasorelaxation and hypertension, as well as augmented neointima formation after vascular injury. Clinical studies indicate that plasma adiponectin concentration is lower in patients with essential hypertension and ischemic heart disease. Raising endogenous adiponectin level or increasing the sensitivity to this hormone may be a promising therapeutic strategy for patients with metabolic and cardiovascular diseases. Among currently used drugs, thiazolidinediones (peroxisome proliferator activated receptor gamma agonists) are most effective in elevating adiponectin level.
 ...
PMID:Adiponectin and its role in cardiovascular diseases. 1833 52

Adiponectin is a recently discovered protein that seems to be exclusively secreted by adipocytes and is the most abundant adipose tissue-derived protein. While some recent studies have demonstrated an association between adiponectin levels and hypertension, these studies were cross-sectional in design, and the results have been inconsistent. Therefore we performed a prospective study to elucidate the role of adiponectin in the development of hypertension. The results of this study showed that serum adiponectin levels were significantly lower in hypertensive subjects than in normotensive subjects. Moreover, in logistic regression analysis, the subjects in the lowest quartile had a 3.72-fold higher risk than those in the highest quartile. Even after adjusting for potential confounding factors, this association was found to be significant. Low serum adiponectin levels were found to be independently associated with a higher risk for the development of hypertension. Our results therefore suggest that hypoadiponectinemia is a novel predictor of hypertension.
 ...
PMID:Adiponectin levels associated with the development of hypertension: a prospective study. 1836 41

The metabolic syndrome (MS) is a clustering of cardiovascular risk factors, with insulin resistance as a major feature. This syndrome has been variously defined, but generally consists of 3 or more of the following components: hyperglycemia, hypertension, hypertriglyceridemia, low HDL, and increased abdominal circumference and/or BMI at >30 kg/m(2). The WHO criteria require the presence of insulin resistance to make the diagnosis. The current review focuses particularly on the association of the MS and the proinflammatory state as well as treatment options to prevent the development of coronary heart disease (CHD). Chronic inflammation is frequently associated with the MS. Inflammatory markers that have been associated with MS include hs-CRP, TNF-alpha, fibrinogen, and IL-6, among others. The link between inflammation and the MS is not fully understood. One postulated mechanism is that these cytokines are released into the circulation by adipose tissue, stimulating hepatic CRP production. The prothrombotic molecule PAI-1 is also increased in the MS. Adiponectin, produced exclusively by adipocytes, is decreased in obesity. The association of these proinflammatory and prothrombotic markers with the MS is discussed in detail. The general goals of treatment of the MS are prevention of CHD events and diabetes if not already present. The approach to treatment of those with the MS should include lifestyle changes, including weight loss and exercise as well as appropriate pharmacological therapies. Certain medications, which may be used in persons with MS, have been shown to have beneficial effects on clinical outcome and/or anti-inflammatory effects.
 ...
PMID:The metabolic syndrome and inflammation. 1837 Jun 40


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>